Literature DB >> 11576927

Effect of chronic renal failure on nitric oxide metabolism.

N D Vaziri1.   

Abstract

Chronic renal failure (CRF) is associated with hypertension, endothelial dysfunction, and a strong propensity for arteriosclerotic cardiovascular disease. Nitric oxide (NO) is an endogenous modulator with diverse biological functions. Chronic inhibition of NO synthases (NOS) has been shown to cause hypertension and vasculopathy. In light of these considerations, numerous studies have explored the effect of CRF on NO metabolism with the assumption that NO deficiency may be involved in the pathogenesis of cardiovascular and other consequences of uremia. The purpose of this review is to provide a brief overview of the effect of CRF on (1) the bioavailability of NO substrate, L-arginine; (2) the expression of NOS isoforms in the relevant organs; (3) the interaction of NO with reactive oxygen species that are known to be increased in CRF, and (4) the accumulation of uremic inhibitors of NOS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576927     DOI: 10.1053/ajkd.2001.27409

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Authors:  Wanghui Jing; Nosratola D Vaziri; Ane Nunes; Yasunori Suematsu; Ted Farzaneh; Mahyar Khazaeli; Hamid Moradi
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors.

Authors:  Kaan Gökçen; Hakan Kılıçarslan; Burhan Coşkun; Alparslan Ersoy; Onur Kaygısız; Yakup Kordan
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

3.  Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial.

Authors:  Samuel Headley; Michael Germain; Richard Wood; Jyovani Joubert; Charles Milch; Elizabeth Evans; Anthony Poindexter; Allen Cornelius; Britton Brewer; Linda S Pescatello; Beth Parker
Journal:  Am J Kidney Dis       Date:  2014-04-26       Impact factor: 8.860

Review 4.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 5.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

Review 6.  Cardiovascular risk and management in chronic kidney disease.

Authors:  Diana Rucker; Marcello Tonelli
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

7.  The assessment of oxidative stress on patients with chronic renal failure at different stages and on dialysis patients receiving different hypertensive treatment.

Authors:  Servin Yeşil Günal; Bilal Ustündağ; Ali İhsan Günal
Journal:  Indian J Clin Biochem       Date:  2013-03-26

8.  Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease.

Authors:  Y Bai; W Sigala; G R Adams; N D Vaziri
Journal:  Am J Nephrol       Date:  2008-09-17       Impact factor: 3.754

9.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.

Authors:  Nosratola D Vaziri; Hamid Moradi; Madeleine V Pahl; Alan M Fogelman; Mohamad Navab
Journal:  Kidney Int       Date:  2009-05-27       Impact factor: 10.612

Review 10.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.